Nephros, Inc. (NEPH) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↓
26.34
↓-60% vs avg
5yr avg: 65.40
30Y Low38.2·High92.6
P/FCF
↓
23.23
↓-42% vs avg
5yr avg: 40.16
30Y Low32.5·High47.8
P/B Ratio
↑
3.78
+13% vs avg
5yr avg: 3.34
30Y Low0.9·High30.9
ROE
↑
12.7%
↓+167% vs avg
5yr avg: -18.9%
30Y Low-488%·High13%
Debt/EBITDA
↓
0.83
↓-85% vs avg
5yr avg: 5.35
30Y Low0.8·High9.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NEPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nephros, Inc. trades at 32.0x earnings, 75% below its 5-year average of 127.2x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 44%. On a free-cash-flow basis, the stock trades at 23.2x P/FCF, 42% below the 5-year average of 40.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $38M | $54M | $16M | $36M | $12M | $59M | $78M | $75M | $35M | $24M | $18M |
| Enterprise Value | $34M | $49M | $13M | $33M | $9M | $53M | $72M | $73M | $33M | $23M | $19M |
| P/E Ratio → | 32.00 | 44.36 | 210.00 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.03 | 2.85 | 1.10 | 2.52 | 1.20 | 5.78 | 9.10 | 7.26 | 6.18 | 6.25 | 7.75 |
| P/B Ratio | 3.78 | 5.25 | 1.82 | 4.30 | 1.34 | 4.01 | 5.00 | 9.76 | 5.17 | 12.22 | 26.95 |
| P/FCF | 23.23 | 32.54 | — | 47.79 | — | — | — | — | — | — | — |
| P/OCF | 23.23 | 32.54 | — | 43.45 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NEPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Nephros, Inc.'s enterprise value stands at 26.3x EBITDA, 60% below its 5-year average of 65.4x. The Healthcare sector median is 14.4x, placing the stock at a 84% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.62 | 0.93 | 2.35 | 0.94 | 5.20 | 8.39 | 7.11 | 5.73 | 6.12 | 7.99 |
| EV / EBITDA | 26.34 | 38.25 | 92.56 | — | — | — | — | — | — | — | — |
| EV / EBIT | 29.56 | 42.92 | 147.07 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 29.90 | — | 44.50 | — | — | — | — | — | — | — |
NEPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nephros, Inc. earns an operating margin of 6.1%. Operating margins have expanded from -11.2% to 6.1% over the past 3 years, signaling improving operational efficiency. ROE of 12.7% is modest. ROIC of 14.2% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.1% | 61.1% | 61.6% | 59.0% | 47.4% | 55.1% | 57.4% | 58.9% | 56.3% | 60.2% | 55.8% |
| Operating Margin | 6.1% | 6.1% | 0.0% | -11.2% | -43.5% | -31.8% | -49.9% | -30.5% | -53.0% | -58.4% | -123.7% |
| Net Profit Margin | 6.4% | 6.4% | 0.5% | -11.1% | -74.0% | -40.2% | -55.7% | -33.1% | -59.8% | -21.2% | -130.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.7% | 12.7% | 0.9% | -18.3% | -62.5% | -27.1% | -41.0% | -47.2% | -77.8% | -61.8% | -182.0% |
| ROA | 9.6% | 9.6% | 0.6% | -13.8% | -51.5% | -22.7% | -31.6% | -30.8% | -43.8% | -21.1% | -91.2% |
| ROIC | 14.2% | 14.2% | 0.1% | -19.5% | -43.0% | -26.7% | -41.2% | -45.9% | -79.8% | -126.0% | -162.6% |
| ROCE | 11.2% | 11.2% | 0.1% | -16.5% | -34.9% | -20.0% | -32.4% | -36.9% | -54.8% | -90.9% | -119.7% |
NEPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Nephros, Inc. carries a Debt/EBITDA ratio of 0.8x, which is very conservative (75% below the sector average of 3.3x). The company holds a net cash position — cash of $5M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 1146.0x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.16 | 0.22 | 0.12 | 0.07 | 0.14 | 0.33 | 0.30 | 0.85 | 1.26 |
| Debt / EBITDA | 0.83 | 0.83 | 9.87 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.43 | -0.27 | -0.30 | -0.29 | -0.40 | -0.39 | -0.21 | -0.38 | -0.27 | 0.84 |
| Net Debt / EBITDA | -3.37 | -3.37 | -16.43 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.64 | — | -3.29 | — | — | — | — | — | — | — |
| Interest Coverage | 1146.00 | 1146.00 | 90.00 | -786.50 | -212.85 | -66.90 | -40.15 | -16.46 | -18.87 | -7.60 | -16.63 |
Net cash position: cash ($5M) exceeds total debt ($1M)
NEPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Nephros, Inc.'s current ratio of 4.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.89x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.98x to 4.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.06 | 4.06 | 5.31 | 3.98 | 5.85 | 5.70 | 11.44 | 3.42 | 3.08 | 2.04 | 1.41 |
| Quick Ratio | 2.89 | 2.89 | 3.64 | 2.81 | 3.62 | 3.84 | 7.43 | 2.36 | 2.38 | 1.68 | 0.88 |
| Cash Ratio | 1.95 | 1.95 | 2.41 | 2.04 | 2.57 | 2.92 | 6.23 | 1.72 | 1.73 | 1.18 | 0.34 |
| Asset Turnover | — | 1.38 | 1.26 | 1.20 | 0.91 | 0.58 | 0.46 | 0.89 | 0.54 | 0.76 | 0.87 |
| Inventory Turnover | 2.26 | 2.26 | 2.08 | 2.36 | 1.66 | 1.03 | 0.69 | 1.66 | 1.33 | 2.25 | 2.14 |
| Days Sales Outstanding | — | 46.90 | 45.90 | 38.35 | 47.06 | 58.62 | 58.15 | 44.86 | 93.19 | 80.11 | 61.04 |
NEPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nephros, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 3.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 2.3% | 0.5% | — | — | — | — | — | — | — | — |
| FCF Yield | 4.3% | 3.1% | — | 2.1% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $11M | $10M | $10M | $10M | $9M | $8M | $7M | $6M | $5M |
Peer Comparison
Compare NEPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NEPHYou | $38M | 32.0 | 26.3 | 23.2 | 61.1% | 6.1% | 12.7% | 14.2% | 0.8 |
 CNMD | $1B | 24.3 | 10.0 | 7.5 | 52.8% | 10.3% | 4.7% | 5.8% | 4.3 |
 NVCR | $2B | -14.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ANGO | $466M | -13.5 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 NX | $925M | -3.7 | — | 9.0 | 27.2% | -10.6% | -28.9% | -8.8% | — |
 FELE | $4B | 30.6 | 13.7 | 22.7 | 35.5% | 12.7% | 11.3% | 14.7% | 0.8 |
 CWCO | $525M | — | -4.7 | 0.0 | 36.6% | 13901508.9% | 0.0% | 26.6% | 0.0 |
 DHR | $121B | 34.0 | 17.8 | 23.0 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 PEN | $13B | 71.3 | 61.5 | 72.4 | 67.1% | 13.5% | 13.8% | 11.3% | 1.1 |
 XRAY | $2B | -3.7 | 7.2 | 21.2 | 50.0% | 6.8% | -36.4% | 5.1% | 4.1 |
 WAT | $23B | 33.0 | 21.8 | 42.9 | 57.8% | 28.2% | 29.3% | 20.3% | 1.3 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See NEPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NEPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NEPH vs CNMD
Side-by-side business, growth, and profitability comparison vs CONMED Corporation.
Start ComparisonNEPH — Frequently Asked Questions
Quick answers to the most common questions about buying NEPH stock.
What is Nephros, Inc.'s P/E ratio?
Nephros, Inc.'s current P/E ratio is 32.0x. The historical average is 44.4x.
What is Nephros, Inc.'s EV/EBITDA?
Nephros, Inc.'s current EV/EBITDA is 26.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 65.4x.
What is Nephros, Inc.'s ROE?
Nephros, Inc.'s return on equity (ROE) is 12.7%. The historical average is -123.7%.
Is NEPH stock overvalued?
Based on historical data, Nephros, Inc. is trading at a P/E of 32.0x. Compare with industry peers and growth rates for a complete picture.
What are Nephros, Inc.'s profit margins?
Nephros, Inc. has 61.1% gross margin and 6.1% operating margin.
How much debt does Nephros, Inc. have?
Nephros, Inc.'s Debt/EBITDA ratio is 0.8x, indicating low leverage. A ratio below 2x is generally considered financially healthy.